SGK
VRTX icon

Steigerwald Gordon & Koch’s Vertex Pharmaceuticals VRTX Stock Holding History

Steigerwald Gordon & Koch’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.6K Hold
167
– – 0.01% 250
2025
Q4 		$75.7K Hold
167
– – 0.01% 253
2025
Q3 		$65.4K Buy
+167
New +$69.8K 0.01% 264

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Steigerwald Gordon & Koch's VRTX Position: Q1 2026 in Review

Steigerwald Gordon & Koch held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 167 shares worth $74.6K. The position accounts for 0.01% of the portfolio, ranked #250.

Steigerwald Gordon & Koch first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $75.7K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Steigerwald Gordon & Koch held 167 shares of Vertex Pharmaceuticals worth $74.6K as of Q1 2026.
  • Steigerwald Gordon & Koch left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.01% of Steigerwald Gordon & Koch's portfolio in Q1 2026, its #250 holding.
  • Steigerwald Gordon & Koch first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Steigerwald Gordon & Koch's Vertex Pharmaceuticals position peaked at $75.7K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q1 2026, filed 28 Apr 2026.